MX9701859A - Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos. - Google Patents

Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos.

Info

Publication number
MX9701859A
MX9701859A MX9701859A MX9701859A MX9701859A MX 9701859 A MX9701859 A MX 9701859A MX 9701859 A MX9701859 A MX 9701859A MX 9701859 A MX9701859 A MX 9701859A MX 9701859 A MX9701859 A MX 9701859A
Authority
MX
Mexico
Prior art keywords
colon carcinoma
monoclonal antibodies
associated antigens
human colon
antibodies against
Prior art date
Application number
MX9701859A
Other languages
English (en)
Inventor
Kwong Y Tsang
Myron Arlen
Original Assignee
Kwong Y Tsang
Myron Arlen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kwong Y Tsang, Myron Arlen filed Critical Kwong Y Tsang
Publication of MX9701859A publication Critical patent/MX9701859A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen anticuerpos monoclonales, en particular 233.28 y 33.1 y anticuerpos quiméricos, en particular Chi # 1 quimérico raton/humano específico para antígenos de glicoproteína de antígenos asociados con carcinoma de colon, los cuales son inmunogénicos en los seres humanos. Tales anticuerpos, y los fragmentos y derivados de los mismo, son utiles en inmunodiagnosis e inmunoterapia de cáncer de colon, de pecho y de ovario humanos, y para la purificacion de antígenos, los cuales pueden servir como agentes inmunoterapéuticos. Se describen también métodos para detectar el antígeno asociado al carcinoma de colon en una muestra, y los métodos para tratar sujetos que tienen carcinomas de colon, de pecho y de ovario.
MX9701859A 1994-09-12 1997-03-12 Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos. MX9701859A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/304,524 US5688657A (en) 1988-03-31 1994-09-12 Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor

Publications (1)

Publication Number Publication Date
MX9701859A true MX9701859A (es) 1998-07-31

Family

ID=23176896

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701859A MX9701859A (es) 1994-09-12 1997-03-12 Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos.

Country Status (10)

Country Link
US (1) US5688657A (es)
EP (1) EP0777690A4 (es)
JP (1) JPH10505749A (es)
KR (1) KR970706307A (es)
AU (1) AU3587095A (es)
CA (1) CA2199740A1 (es)
IL (1) IL115232A0 (es)
MX (1) MX9701859A (es)
WO (1) WO1996008514A1 (es)
ZA (1) ZA957634B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
EP1291657A3 (en) 1996-01-30 2003-08-27 Exact Sciences Corporation Methods for detecting colon cancer from stool samples
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US6247995B1 (en) 1996-02-06 2001-06-19 Bruce Bryan Bioluminescent novelty items
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US7361346B1 (en) * 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
NZ516264A (en) * 1996-05-15 2002-04-26 Altarex Inc Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
BR9815289A (pt) * 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
US20050260177A1 (en) * 1998-06-05 2005-11-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
JP2002525031A (ja) * 1998-08-04 2002-08-13 ダイアデクスアス・インコーポレーテッド 大腸癌の診断、監視、病期決定、画像処理及び治療の新規方法
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
AU756398B2 (en) * 1999-03-11 2003-01-09 Smithkline Beecham Biologicals (Sa) Novel compounds
US6693176B1 (en) * 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2410895A1 (en) * 2000-05-31 2001-12-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
US6801270B2 (en) * 2000-06-26 2004-10-05 Reveo, Inc. Backlight for a liquid crystal display having high light-recycling efficiency
JP2004529849A (ja) * 2000-09-01 2004-09-30 インターナショナル バイオイムン システムズ，インコーポレーテッド 扁平上皮癌に対する特異的モノクローナル抗体の同定と開発
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
ES2619313T3 (es) * 2001-03-15 2017-06-26 Precision Biologics, Inc. Terapia de anticuerpos monoclonales para el cáncer de páncreas
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP3184539A3 (en) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antibodies
US7935338B2 (en) * 2001-12-11 2011-05-03 University Of Massachusetts Antibodies to treat cancer
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
US7569673B2 (en) 2002-06-28 2009-08-04 The United States Of America As Represented By The Department Of Health And Human Services Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors
WO2004009632A2 (de) * 2002-07-22 2004-01-29 Nemod Immuntherapie Ag Verfahren zur herstellung eines immunstimulatorischen muzins (muc1)
KR101388611B1 (ko) 2002-10-16 2014-04-23 퍼듀 퍼머 엘피 세포-연관된 ｃａ 125/ｏ772ｐ에 결합하는 항체들 및 그것의 용도의 방법들
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US7589181B2 (en) * 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
CA2571743A1 (en) * 2004-06-30 2006-01-12 International Bioimmune Systems, Inc. Humanized monoclonal antibody 31.1 as an anticancer agent
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
EP1871417B1 (en) * 2005-04-15 2013-09-11 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
WO2007044071A2 (en) 2005-04-21 2007-04-19 Exact Sciences Corporation Analysis of heterogeneous nucleic acid samples
CN101688183A (zh) * 2007-05-07 2010-03-31 霍夫曼-拉罗奇有限公司 减轻癌性疾病的抗体
EP2217625B1 (en) 2007-11-08 2021-08-04 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
EP2445932B1 (en) 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
US20150231077A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens

Also Published As

Publication number Publication date
IL115232A0 (en) 1995-12-31
AU3587095A (en) 1996-03-29
EP0777690A4 (en) 2000-07-05
WO1996008514A1 (en) 1996-03-21
CA2199740A1 (en) 1996-03-21
EP0777690A1 (en) 1997-06-11
KR970706307A (ko) 1997-11-03
JPH10505749A (ja) 1998-06-09
US5688657A (en) 1997-11-18
ZA957634B (en) 1996-05-27

Similar Documents

Publication Publication Date Title
MX9701859A (es) Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos.
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
WO2003099196A3 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP0823913A4 (en) SYNTHESIS OF THE BREAST TUMOR ASSOCIATED ANTIQUE DEFINED BY THE MONOCLONAL ANTIBODY MBR1 AND ITS USE
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
GEP20084476B (en) Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours
KR910700077A (ko) 인체 종양과 관련된 신규 항원에 대한 신규한 모노클로날 항체
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
DK0586002T3 (da) Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
ATE128986T1 (de) Antigen sf-25 des darm-adenokarzinoms sowie antikörper, die dieses antigen erkennen.
EP1411962A4 (en) MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER
KR900701318A (ko) 항-사람 고분자량- 흑색종 관련 항원에 대한 항-이디오 타입 항체
ATE292681T1 (de) E-cadherin-mutationen als grundlage zur diagnostik und therapie humaner maligner tumoren
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
ZA927785B (en) Monoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereof
GR3020387T3 (en) Ctaa 28a32, the antigen recognized by mca 28a32
ZA884777B (en) Antigen recognized by mca 16 88
WO1999043815A3 (en) Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof
GR890100333A (en) Antihuman antigen antibodies
DE69229829D1 (de) Tumorspezifischer monoklonaler antikörper 81av78